Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of KCONVAC in Healthy Adults
NCT04756323Phase 2Unknown
- Sponsor
- Beijing Minhai Biological
- Start
- Oct 2020
- Primary completion
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of COVID-19 vaccine (Vero cell), inactivated in coronavirus disease 2019 (COVID-19), sponsored by Beijing Minhai Biological. Status: unknown.
02
Drugs
COVID-19 vaccine (Vero cell), inactivated
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04756323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04756323.